RPG Life Sciences Ltd
₹ 2,324
-0.31%
13 Jan
10:04 a.m.
About
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
Key Points
- Market Cap ₹ 3,844 Cr.
- Current Price ₹ 2,324
- High / Low ₹ 2,725 / 1,772
- Stock P/E 34.5
- Book Value ₹ 335
- Dividend Yield 0.84 %
- ROCE 32.8 %
- ROE 25.5 %
- Face Value ₹ 8.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 28.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
- Company has been maintaining a healthy dividend payout of 27.1%
Cons
- The company has delivered a poor sales growth of 11.7% over past five years.
- Earnings include an other income of Rs.139 Cr.
- Debtor days have increased from 35.3 to 48.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 666 | |
| 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 517 | |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 149 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 22% |
| 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 139 | |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 267 |
| Tax % | 18% | -0% | -0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | |
| 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 215 | |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 130.25 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 44% |
| 3 Years: | 39% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 541 |
| 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | -0 | -0 | -0 | |
| 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 152 | |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
| 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 179 | |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 27 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 58 | 91 | 127 | 93 |
| 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 407 | |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6 | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | |
| 59 | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | |
| -54 | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | |
| Net Cash Flow | 0 | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 30 | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jan
- Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Jan
-
Disclosure Under Regulation 30 Of SEBI LODR, 2015 For Details Of Order Received From GST Authority, Maharashtra
29 Dec - GST order dated Dec 29, 2025: demand Rs1,07,81,869 for Apr 2021-Mar 2022.
-
Incorporation Of A Wholly Owned Subsidiary.
24 Dec - RPG Life Sciences incorporated wholly-owned subsidiary RPG Active Pharma Limited on Dec 24, 2025 (CIN U21001MH2025PLC464091).
- Closure of Trading Window 24 Dec
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Oct 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jun 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Jun 2016TranscriptAI SummaryPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs